THE USE OF PUBLISHED REAL-WORLD EVIDENCE IN HTA: AN ANALYSIS OF THE EVIDENCE BASE OF COMPANY SUBMISSIONS IN 2016 NICE APPRAISALS

被引：0
|
作者：
Van Lier, H. [1 ]
de Boeck, M. [1 ]
Edwards, V [1 ]
Hanekamp, E. [1 ]
Hartog, T. E. [1 ]
Richmond, G. [1 ]
van den Broek, R. [1 ]
机构：
[1] Excerpta Medica, Amsterdam, Netherlands
来源：
VALUE IN HEALTH | 2017年 / 20卷 / 09期
关键词：
D O I：
10.1016/j.jval.2017.08.076
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
HT8
引用
收藏
页码：A410 / A410
页数：1
相关论文
共 50 条
  • [1] USE OF REAL-WORLD EVIDENCE IN HTA SUBMISSIONS IN EMERGING MARKETS
    Babic, T.
    Roberts, W. M.
    Astill, J.
    Styhler, A.
    Smith, Sa
    VALUE IN HEALTH, 2024, 27 (12)
  • [2] GLOBAL USE OF NORDIC REAL-WORLD EVIDENCE: A SYSTEMATIC REVIEW OF PUBLISHED LITERATURE AND HTA SUBMISSIONS
    Kaushik, P.
    Grip, Toresson E.
    Lueza, B.
    Arya, S.
    Singh, N.
    Nanda, S.
    Grover, R.
    Afaque, A.
    Syal, K.
    VALUE IN HEALTH, 2023, 26 (12) : S531 - S531
  • [3] THE USE OF REAL-WORLD EVIDENCE IN NICE HEALTH TECHNOLOGY APPRAISALS: A QUANTITATIVE REVIEW OF SUBMISSIONS TO NICE BETWEEN 2022 AND 2024
    Aidarous, A.
    Tahir, H.
    Diribe, O.
    Allen, R.
    VALUE IN HEALTH, 2024, 27 (12) : S358 - S358
  • [4] The use of real-world data/evidence in regulatory submissions
    Song, Fuyu
    Zang, Chenxuan
    Ma, Xinyi
    Hu, Sifan
    Sun, Qiqing
    Chow, Shein-Chung
    Sun, Hongqiang
    CONTEMPORARY CLINICAL TRIALS, 2021, 109
  • [5] COMPARISON OF THE USE OF REAL-WORLD EVIDENCE FOR CLINICAL EFFECTIVENESS IN HTA PRE- AND POSTINTRODUCTION OF THE NICE FRAMEWORK
    Mackley, R.
    Green, R.
    Shrivastava, M.
    Chasimpha, S.
    Teague, R.
    VALUE IN HEALTH, 2023, 26 (12) : S390 - S391
  • [6] THE USE OF REAL-WORLD EVIDENCE IN FDA REGULATORY SUBMISSIONS: A REVIEW
    Raina, N.
    Ko, J.
    VALUE IN HEALTH, 2023, 26 (06) : S381 - S381
  • [7] THE VALUE OF REAL-WORLD EVIDENCE (RWE) IN MELANOMA IN HEALTH TECHNOLOGY ASSESSMENT (HTA) APPRAISALS
    Shah, R.
    Gautam, R.
    Rai, M. K.
    Prasanna, R.
    VALUE IN HEALTH, 2022, 25 (12) : S317 - S317
  • [8] IMPACT OF REAL-WORLD EVIDENCE IN THE HTA PROCESS IN FRANCE: ANALYSIS OF TRANSPARENCY COMMISSION APPRAISALS IN RARE DISEASES
    Akhamlich, I
    Lefevre, C.
    Schmidely, N.
    Vega, Ramirez C.
    Marquet, T.
    VALUE IN HEALTH, 2024, 27 (12) : S371 - S371
  • [9] A SYSTEMATIC LITERATURE REVIEW ON THE USE OF REAL-WORLD EVIDENCE IN NICE TECHNOLOGY APPRAISALS INDICATED FOR MULTIPLE MYELOMA
    Dempsey, J.
    Tsang, C.
    Duffield, C.
    VALUE IN HEALTH, 2023, 26 (12) : S520 - S520
  • [10] ANALYSIS OF REAL-WORLD EVIDENCE AND REAL-WORLD DATA BY CONITEC, BRAZILIAN HTA AGENCY
    Nita, M. E.
    Riveros, B. S.
    Vaz, P.
    Mussolino, F.
    VALUE IN HEALTH, 2016, 19 (03) : A286 - A286
12345